How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
Can CD163 macrophages help select MSS colorectal cancer patients for regorafenib plus avelumab?
Why IDO1 blockade lowered kynurenine but failed to improve anti-PDL1 efficacy in sarcoma
Does cabozantinib help in advanced Ewing sarcoma and osteosarcoma — and can plasma biomarkers flag who responds?
Why PD-1 blockade falls short in soft-tissue sarcoma — and the macrophage/IDO1 axis behind it
